Freedom Finance and Binance Join Forces in Digital Assets 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
Reese’s Peanut Butter Cup Recipe Debate: Hershey Responds as Cocoa Prices Shift 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Mark Zuckerberg Testifies in Youth Social Media Addiction Trial Over Instagram Policies 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Stock Market Movers: NVIDIA and Meta Expand AI Partnership as Cadence Surges on Earnings 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
DALLAS and FORT WORTH, Texas, May 02, 2018 -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery technologies, today announced that it will report first quarter 2018 financial results prior to the opening of U.S. financial markets on Wednesday, May 9, 2018. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. ET that same day.
The live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 1988619. A live audio webcast for the conference call will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING), and Adzenys ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information, including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. Additional information about Neos is available at www.neostx.com.
| Contacts: | ||
| Richard Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408-1389 [email protected] | Sarah McCabe Senior Vice President Stern Investor Relations, Inc. (212) 362-1200 [email protected] | |
